Reviva Pharmaceuticals Raises $10M in Public Offering to Fund Schizophrenia Trial
Event summary
- Reviva Pharmaceuticals closed a $10M public offering on March 20, 2026, selling 6.67M shares of common stock and accompanying warrants.
- The offering included Series G and Series H warrants with an exercise price of $1.50 per share.
- Proceeds will fund the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia and general corporate purposes.
- Post-offering, Reviva has approximately $23M in cash, expected to last into Q1 2027.
The big picture
Reviva's $10M public offering underscores the financial pressures facing late-stage biopharmaceutical companies as they navigate costly clinical trials. The funding will support its schizophrenia treatment candidate, brilaroxazine, a critical milestone given the high unmet needs in CNS disorders. The offering also highlights the reliance on institutional investors in the healthcare sector, particularly for companies with specialized pipelines.
What we're watching
- Trial Execution
- How the RECOVER-2 Phase 3 trial for brilaroxazine progresses and whether it meets regulatory milestones.
- Cash Burn
- The pace at which Reviva's $23M cash reserve depletes and its ability to secure additional funding if needed.
- Market Positioning
- Whether Reviva can differentiate itself in the competitive CNS therapeutics space.
Related topics